Unibest 优贝德
Login / Register
API (Commercialized)GMP/DMFAnti-infective / Transplant

Letermovir

Prophylaxis of cytomegalovirus (CMV) infection in adult recipients of allogeneic hematopoietic stem cell transplant

CAS No.
917389-32-3
Indication Class
Anti-infectives
Patent Expiry
Off-patent · 2026 (indicative)
Therapeutic Area
Anti-infective / Transplant
Labeled Purity
98%+
Registration Readiness
GMP/DMF
Commercialization Tier
API (Commercialized)
Linked Intermediates
4 key intermediates available
Patent Scope
US / EU compound patent
First-in-class CMV Terminase InhibitorTransplant Specialty

Key Intermediates for This API

Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher

Listing Logic · Why It's Worth Listing

A first-in-class CMV terminase inhibitor replacing older ganciclovir-class agents with a better safety profile; a niche, high-value specialty API with limited competition.

Demand

Anti-infective / Transplant · Marketed; available for immediate sourcing

Compliance

GMP/DMF-ready; supports regulatory filing and audit in target markets

Supply

4 key intermediates available; scale-up and cost control manageable

Product Description

Letermovir is a first-in-class antiviral medication designed to prevent cytomegalovirus (CMV) infection in adults who have received an allogeneic hematopoietic stem cell transplant (HSCT).

Supply source: Unibest · Letermovir, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.